CTOR (Citius Oncology) Short-Term Debt: $0.00 Mil (As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.68
! 2 Warning Signs
View Full Analysis

What is Citius Oncology Short-Term Debt?

Citius Oncology CTOR -2.10% 10 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Citius Oncology's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Citius Oncology Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Citius Oncology Short-Term Debt Related Terms

Citius Oncology Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Citius Oncology's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology Short-Term Debt Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
Short-Term Debt
0.00 0.00 0.00 0.00

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CTOR
10GF Score
Citius Oncology Inc CTOR
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Citius Oncology (CTOR) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is Citius Oncology's Short-Term Debt too high?
Citius Oncology's current Short-Term Debt is $0.00 Mil. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Short-Term Debt compare to INCR and TLPH?
Citius Oncology's Short-Term Debt of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Citius Oncology's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price